2019
DOI: 10.1186/s13046-019-1404-8
|View full text |Cite
|
Sign up to set email alerts
|

Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells

Abstract: Background Tamoxifen resistance presents a huge clinical challenge for breast cancer patients. An understanding of the mechanisms of tamoxifen resistance can guide development of efficient therapies to prevent drug resistance. Methods We first tested whether peptidylarginine deiminase 2 (PAD2) may be involved in tamoxifen-resistance in breast cancer cells. The effect of depleting or inhibiting PAD2 in tamoxifen-resistant MCF-7 (MCF7/… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
49
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 87 publications
(49 citation statements)
references
References 49 publications
0
49
0
Order By: Relevance
“…Two of these proteins, PADI2 (described above) and UCHL1, are potentially directly druggable 38,39 and exhibited increased total protein expression in all FBXW7 ‐mutant derivative cell lines across two genomically distinct backgrounds. Interestingly, UCHL1 promotes p53 signaling in nasopharyngeal carcinoma 40 and PADI2 facilitates p53 degradation in breast cancer cells 22 . This raises the possibility that the increase in PADI2 we observe is a response to increased UCHL1 protein expression, or vice versa.…”
Section: Discussionmentioning
confidence: 73%
See 1 more Smart Citation
“…Two of these proteins, PADI2 (described above) and UCHL1, are potentially directly druggable 38,39 and exhibited increased total protein expression in all FBXW7 ‐mutant derivative cell lines across two genomically distinct backgrounds. Interestingly, UCHL1 promotes p53 signaling in nasopharyngeal carcinoma 40 and PADI2 facilitates p53 degradation in breast cancer cells 22 . This raises the possibility that the increase in PADI2 we observe is a response to increased UCHL1 protein expression, or vice versa.…”
Section: Discussionmentioning
confidence: 73%
“…Compared to normal tissue, PADI2 protein is increased in breast, cervical, colon, liver, lung, ovarian serous, thyroid, 20 and prostate cancers 21 . PADI2 mRNA expression is upregulated in tamoxifen‐resistant 22 and HER2/ERBB2 + breast cancers 23 . In contrast, in colon cancer, PADI2 mRNA and protein are decreased 24,25 and low mRNA correlates with poor prognosis 24 …”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, PAD2 participates in drug resistance in breast cancer. PAD2 is highly upregulated in tamoxifen‐resistant MCF‐7 cells, and depletion of the PADI 2 gene or inhibition of PAD2 restores the sensitivity of these cells to tamoxifen 44 . Notably, inhibiting PAD2 with Cl‐amidine enhances the effects of docetaxel on tamoxifen‐resistant MCF‐7 cells 44 .…”
Section: Roles Of Pad2 and Pad4 In Cancersmentioning
confidence: 99%
“…In addition, increased PAD2 enrichment on the PTN and MAGEA12 gene promoters has been detected in PADI2-overexpressing MCF-7 cells. 23 Citrullination on the histone H3 tail (at arginine residues 2, 8 and 17) on both the MAGEA12 and PTN gene promoters declines as PAD2 is depleted, suggesting that PAD2 regulates gene expression through histone tail citrullination.PADI2 gene or inhibition of PAD2 restores the sensitivity of these cells to tamoxifen 44. Notably, inhibiting PAD2 with Cl-amidine enhances the effects of docetaxel on tamoxifen-resistant MCF-7 cells 44.…”
mentioning
confidence: 99%
See 1 more Smart Citation